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Abstract
The performance of polyclonal monospecific rabbit anti-sera raised against synthetic peptides
derived from conserved HCV sequences of genotype 4 was evaluated for efficient detection of viral
core and E1 antigens in circulating immune complexes (ICs) precipitated from 65 serum samples
of HCV patients. The infection was established in those patients by the presence of HCV RNA in
their sera. A novel enzyme-linked immunosorbent assay (ELISA) was developed for the detection
of HCV core and E1 antigen in serum samples. Western blot analyses were used to demonstrate
the presence of the core and E1 target antigen in serum samples. The mean OD readings of both
core and E1 antigens were significantly higher (P < 0.05) among the viremic patients when
compared to controls. Also a significant positive correlation (P < 0.05, r = 0.98) between the values
of both core and E1 was recorded. Western blot analysis based on monospecific antibodies against
core and E1 recognized the 38-kDa and 88 -kDa bands respectively in the sera of all infected
patients. No specific reaction was observed with the sera from uninfected individuals. Interestingly
the results of core and E1 antigen levels displayed no positive correlation with the HCV copy
number as measured by bDNA. Liver enzymes (ALT and AST) showed a moderate positive
correlation (r = 0.44 and 0.47 respectively) with the viral core antigens level. The same trend holds
true for E1 (r = 0.43 and 0.64 for ALT and AST respectively). HCV load in infected patients revealed
extremely poor correlation with serum ALT and AST levels (r = 0.022 and 0.002 respectively). In
conclusion we present a new combination of serological tools correlating with liver enzyme levels
that could be utilized as supplemental tests to viral load testing. Also, a sensitive and specific
immunoassay was developed for the detection of HCV core and E1 in human serum. This test can
be applied for laboratory diagnosis of HCV infection.
Background
The genome of Hepatitis C Virus (HCV) consists of 5' and
3' untranslated regions that flank a single open reading
frame (ORF) encoding structural and non-structural pro-
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teins [1] The structural proteins of HCV include the capsid
(core) protein and two envelope glycoproteins (E1 and
E2). Around 80% of infected individuals develop chronic
infections, more than 2% of the globe is chronically
infected and infection is the main etiological agent of
chronic hepatitis, liver cirrhosis and hepatocellular carci-
noma [2] Among the mechanisms the virus exerts to per-
sist infection are, down regulating expression of its
glycoproteins on cell surface, thus reducing the possibility
of antibody recognition and destruction of infected cells,
interference with the correct expression of major histo-
compatibility complexes (MHCs) on the cell surface or
blocking antiviral immune responses such as the release
of interferons (IFNs) and complement-mediated lysis
[3,4], however, it is still not clear whether liver damage is
directly caused by infection or results from host's immune
reactions. Accumulation of mutations during viral replica-
tion results in a significant genetic heterogeneity and this
may be attributed to lack of RNA-dependent RNA
polymerase proofreading activity [1]. These mutations
result in production of closely related, yet heterogeneous
sequences so called quasispecies [[5-7] and [8]]. Such
mutations within either the envelop or the core proteins
may allow blocking of the viral infectivity or increase its
aggression, respectively [9]. It is accepted that each quasis-
pecies functions independently different from other
mutants in terms of its response to neutralizing antibodies
(escape mutants) and induction of liver damage. This was
clearly demonstrated in chimpanzee where antibodies
against HVR1 sequence of a quasispecies could neutralize
its infection but did not function with other quasispecies
[10] and also in patients who develop chronic HCV infec-
tion where the immune system is not entirely capable of
controlling the infection because of the emergence of
multiple escape mutants [11]. Viral mutants differ not
only in their infectivity but also in their intracellular
pathogenesis. Several lines of evidence showed that the
viral core protein plays a key role in development of
hepatic steatosis [12], fibrosis [13] and hepatocellular car-
cinoma [14]. Interestingly, patients were reported to have
mild or absent hepatic changes even though viral loads
are extremely high [15]. These findings suggest that
genomic structure of the quasispecies complex and hence
expression of viral proteins in each case are more influen-
tial factors on the disease morbidity than the more viral
loads. When ALT was used as a marker for liver damage
among HCV patients its level showed positive correlation
with viral load measured by PCR and branched DNA
assays [16]. The same correlation was obtained for both
ALT and AST with viral load [17]. Contradictory results
were reported [18-20] where significant inverse associa-
tion between HCV-RNA and ALT levels was observed.
From those reports it is evident that the available bio-
chemical, molecular and serological tools, although sensi-
tive and specific, cannot allow clear conclusions with
respect to HCV induced pathogenesis in patients infected
with different genotypes. On the other hand for a devel-
oping country like Egypt where genotype 4 is prevailing
[21], there is an increasing need for a supplemental assay
besides the costly molecular quantification of viral RNA
load for sensitive evaluation of the severity of HCV disease
before treatment or during post therapeutic follow ups.
This would help better assessment of early response to the
expensive peg-interferon/ribavirin combined therapy. The
aim of the present work was to evaluate the performance
of home made polyclonal mono-specific antibodies
raised in rabbits against synthetic peptides of conserved
core and envelope sequences as quantitative assays for
HCV core and envelope antigens. Measurements of circu-
lating viral structural proteins were tested as markers for
the degree of liver damage using ALT and AST levels as
indicators. The long term objective was to enhance the
cost effectiveness of therapy via better monitoring of
patients' response.
Materials and methods
1. Human sera
A total of 65 HCV patients were recruited from the Medi-
cal Service Unit of the National Research Center. Diagno-
sis of those patients was based on, clinical examination,
liver enzymes, detectable anti-HCV antibodies in their
sera (Axium HCV Rapid test, Florida, U.S.A.), semi quan-
titative RT-PCR and viral load by bDNA quantitation. A
total of 20 sera collected from healthy human subjects
having no history of any liver complications, undetectable
anti HCV antibodies and negative HCV RNA by RT-PCR in
their sera were included as negative controls.
2. Methods
a. Genotyping
All infected sera included in the study were subjected to
genotyping using Versant HCV Genotype Assay (Lipa;
Bayer, Germany). Briefly, HCV RNA was extracted, fol-
lowed by cDNA synthesis using biotinylated random
primers specific for the 5' UTR of HCV. The generated
biotinylated amplicons were hybridized to immobilized
oligonucleotide probes specific for the 5' UTR of different
HCV genotypes that are bound to nitrocellulose strips by
a poly (T) tail. After hybridization, unhybridized DNA
was washed out from the strips that were then treated with
alkaline phosphatase labeled streptavidin (conjugate)
which bounds then to the biotinylated hybrid. The chro-
mogenic substrate (BCIP/NBT) that allows the formation
of a purple/brown precipitate upon degradation by alka-
line phosphatase of the conjugate was used for visualiza-
tion of the banding pattern on the strip.
b. Reverse Transcription- Polymerase Chain Reaction (RT-PCR)
Total RNA was extracted from different sera using the acid
guanidinium-phenol-chloroform method [[22,23] andVirology Journal 2006, 3:67 http://www.virologyj.com/content/3/1/67
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[24]] then subjected for RT-PCR [25]. In summary, retro-
transcription was performed in 25 μl reaction mixture
containing ~400 ng of the extracted RNA, a final concen-
tration of 0.2 mM from each dNTP (MBI Fermentas; St-
Leon Rot, Germany), 50 pmol of primers 1CH or 2CH for
plus or minus strands respectively and the mixture was
preheated at 92°C for 30 sec then chilled on ice. The
sequence of the primers used was as follows: 1CH : 5'-
GTGCACGGTCTACGAGACCTC-3' 2CH: 5'  AACTACT-
GTCTTCACGCAGAA-3'A total of 40U RNasin (MBI Fer-
mentas; St-Leon Rot, Germany).), 20U of Avian
Myeloblastosis Virus reverse transcriptase and 2.5 μl 10X
enzyme buffer (MBI Fermentas; St-Leon Rot, Germany))
were added to the mixture, the reaction was incubated in
the thermal cycler (T1; Whatman Biometra, Goettingen,
Germany) at 42°C for 60 min, then the enzyme was inac-
tivated and double stranded cDNA was denatured at 95°C
for 10 min and chilled on ice to keep the DNA strands
apart. The amplification of the highly conserved 5'-UTR
sequences was done in 2 rounds of PCR using 2 different
pairs of nested primers, one pair in each round. The
sequence of the primer pair used in the first round was:
Forward (2CH): mentioned above.
Reverse (P2): 5'-TGCTCATGGTGCACGGTCTA-3'
While the sequence of the primer pair used in the second
round was:
Forward (F2): 5'-GTGCAGCCTCCAGGACCC-3'
Reverse (1TS): 5'-GCGACCCAACACTACTCGGCT-3'
Both reactions were carried out in 50 μl volume and the
mixture contained 0.2 mM from each dNTP, 10 μM of
each primer, 5 μl (10X) reaction buffer containing 1.5
mM MgCl2, 10 μl cDNA and 2U Taq DNA polymerase
(Finnzyme Oy; Espoo, Finland). Amplification was car-
ried out for 30 cycles each included 1 min denaturation at
94°C, 1 min annealing at 55°C and 1 min extension at
72° and the last cycle was attached to a final extension
step for 10 min at 72°C followed by soak at 4°C. Ampli-
fication products were analyzed by electrophoresis on
1.5% agarose gel in TBE buffer (0.045 M Tris-borate,
0.001 M EDTA, pH 8.0 [26].
c. Quantitation of viral RNA load
The assay was performed according to manufacturer's
instructions (Versant HCV RNA 3.0 assay bDNA) based
on Elbeik et al., [27]
d. Preparation of immune complexes and ELISA assays
Immune complexes (ICs) were precipitated according to
Juranic et al., [29] by mixing equal volumes of infected or
control sera with freshly prepared borate buffered saline
(25 mM sodium borate, 100 mM boric acid, 75 mM NaCl,
5 mM EDTA disodium salt, pH 8.4) containing 7% poly-
ethylene glycol (PEG-6000) followed by overnight incu-
bation at 4°C then centrifugation at 10,000 rpm for 20
min. The precipitate was resuspended in 50 μl phosphate
buffered saline (PBS) and stored at -20°C till use. ELISA
was based on purified polyclonal rabbit IgG raised against
synthetic core and envelop (E1) peptides specifically
designed based on conserved amino acid sequences
among various viral genotypes Core: IPKARRPEGRT-
WAQPGY, E1: GHRMAWDMM [30]. Those peptides were
previously reported by our group to have more than 90 %
sensitivity and specificity for detecting HCV IgG antibod-
ies in human sera from infected patients [30]. ELISA was
performed according to Maghraby and Bahgat [31] with
minor modifications to early protocol of Engvall and Per-
lman [32]. The assay was carried out in round bottom pol-
yvinyl microtiter plates (ALTO, Italy). Briefly, plates were
coated overnight at 37°C with 100 μl per well of the
diluted ICs in coating buffer (1:100; 1 M Na2CO3; 1 M
NaHCO3, pH 9.6), washed 3 times with PBS containing
0.05% Tween 20 (PBS-T) then blocked with 100 μl/well of
PBS-T containing 1% BSA (PBS-T-BSA) for 2 h at 37°C.
After 3 washes with PBS-T, 100 μl of diluted (1:500) rab-
bit anti-E1 or anti core IgG in PBS-0.05% T-5% -FCS were
incubated for 2 h at 37°C. After 3 washes, antibody bind-
ing was detected using 100 μl/well from 1:500 diluted
peroxidase-labeled anti-rabbit IgG (Sigma Deisenhofen,
Germany). For visualization of the immune reaction, 100
μl/well of OPD substrate (Sigma, Deisenhofen, Germany)
diluted in substrate buffer (0.1 M citric acid anhydrous;
0.2 M dibasic sodium phosphate, pH 5.0) containing
0.06% H2O2 were used and plates were left for 10 min at
room temperature till color development. The enzymatic
reaction was stopped using 40 μl/well 2 M HCl and the
change in optical density (OD) was recorded at λmax 490
nm using a multi-well plate reader (TECAN; SUNRISE,
Austria, GmbH).
e. Detection of HCV core and E1 by Western blotting
Serum samples of infected and non infected individuals
with HCV were subjected to sodium dodecylsulphate
polyacrylamide gel electrophoresis (SDS-PAGE; [33]
through 4% stacking and 16% resolving gels in 0.75 mm-
thick vertical slab gels. Serum samples were diluted, 1: 25
in PBS, mixed with the sample buffer (0.125 M Tris base,
4% SDS, 20% glycerol, 10% mercaptoethanol, and 0.1%
bromophenol blue as a tracking dye) and immediately
boiled for three minutes. A mixture of reference proteins
was run in parallel. Gels were then stained with Coomas-
sie blue. Western blotting was performed as follows:
resolved samples separated by SDS PAGE were electro-
transferred onto nitrocellulose membranes (0.45 mm
pore size). Blotting was carried out at a constant voltage ofVirology Journal 2006, 3:67 http://www.virologyj.com/content/3/1/67
Page 4 of 9
(page number not for citation purposes)
60 volts for two hours. The immunoassay was then per-
formed using rabbit anti-HCV core antibodies diluted 1:
100 in blocking buffer with constant shaking. The blots
were then washed, followed by incubation for 2 h with
goat anti-rabbit IgG alkaline phosphatase conjugate
(Zymed) diluted 1:1000 in Tris-buffered saline [TBS; pH
7.4]. The nitrocellulose membrane was then soaked in
premixed alkaline phosphatase substrate (5-bromo-4-
chloro-3-indolyl phosphate [BCIP], nitro blue tetrazo-
lium [NBT], and 0.1 M Tris buffer, pH 9.6. The color was
observed within 10 minutes and the reaction was stopped
by the addition of distilled water.
Statistical analysis
Standard methods were used to calculate sensitivity, spe-
cificity, efficiency, and positive and negative predictive
values. All parameters were transferred to an IBM PC-AT-
compatible computer for analysis using statistical analysis
program package Instate Software for Science, version 2.3
(Graphpad Software, Inc., San Diego, Calif.). The Mann-
Whitney U test was used to compare the means of two dis-
tributions. Fisher's exact test was used to compare the dif-
ferences between two proportions. P values (two-tailed
test) of less than 0.05 were considered significant.
Results
1. RT-PCR and genotyping
The RT-PCR results on RNA extracted from 65 patient's
sera and 20 uninfected subjects (controls) revealed the
presence of HCV RNA in all infected sera whereas none of
the controls had any detectable HCV RNA. All
patients,sera used were confirmed to be genotype 4
(results not shown).
2. HCV core and E1 OD levels in the precipitated ICs from 
HCV patients' sera
Precipitated immune complexes from 20 sera of healthy
subjects were included as means of negative controls. The
cut off value for both core and E1 was calculated (0.4) as
the mean OD readings obtained from the immune com-
plexes of the healthy control sera plus 2 × standard devia-
tions. The mean OD readings of both core and E1 antigens
were significantly (P < 0.05) higher among the viremic
patients when compared to negative controls (Fig. 1).
ELISA assay based on the detection of the target HCV core
and E1 antigen in serum was developed for the diagnosis
of HCV infection. The mean absorbance values of the
serum samples were 0.697 and 0.644 for Core and E1
respectively (range, 0.411 to 1.250; all positive) for 65
HCV-positive subjects and 0.286 (range, 0.135 to 0.377;
all negative) for 20 healthy human subjects (table 1).
3. Detection of viral core and E1 in HCV patients by 
western blotting
Sera of HCV infected patients who have been confirmed
to be infected with the virus using RT-PCR and had high
titer of both core and E1 viral antigens were used for west-
ern blot analysis. Sera of healthy individuals were
included as negative controls. Results showed that treat-
ment of resolved antigens from infected patients with
anti-sera raised against HCV core peptide resulted in visu-
alization of an immunogenic protein band around ~38
kDa (Fig. 2a.) that was undetectable in sera from the
healthy controls. On the other hand, treatment of
resolved antigens from infected patients with anti-sera
raised against HCV E1 peptide resulted in visualization of
an immunogenic protein band around ~88 kDa (Fig. 2b).
4. Correlation between OD levels of circulating core and 
E1 antigens in HCV infected subjects
OD readings were obtained from ELISA assays on both
core and E1 antigens in the sera of 65 patients. Linear
regression analysis (Fig. 3) showed a strong positive corre-
lation between OD values of both viral antigens (r = 0.98;
P < 0.0).
Scattered plot of the OD values corresponding to circulating  core and envelop HCV antigens in precipitated immune com- plexes from viremic patients in comparison to controls Figure 1
Scattered plot of the OD values corresponding to circulating 
core and envelop HCV antigens in precipitated immune com-
plexes from viremic patients in comparison to controls. The 
cut off values for viral antigens were calculated as the mean 
OD readings obtained from ICs of controls plus 2 × standard 
deviations and was 0.4. The mean OD readings of viral core 
and envelop proteins were significantly higher in viremic 
patients than controls and the P-values for both antigens 
were (<0.0001) and (<0.0003) respectively.
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5. Correlation between levels of both HCV core and E1 
antigens with viral copy number in HCV infected subjects
When the OD readings corresponding to the reactivities of
circulating core (A) and E1 (B) antigens were compared
with the viral load as measured by bDNA assay, the results
reflected absence of correlation between core antigen and
viral-RNA copy number (r = -0.36, P < 0.06) (Fig 4a). Such
absence of correlation was also observed between E1 anti-
gen and viral copy number (r = -0.39, P < 0.05) (Fig 4b)
6. Correlation between HCV core and E1 antigens with the 
levels of ALT and AST
Comparing the OD readings corresponding to the reactiv-
ity of HCV-core antigen with ALT and AST 'levels in
patients sera revealed positive correlation (Fig. 5A &5B)
between the level of the core antigen and both enzymes (r
= 0.44, 0.47 for ALT and AST respectively; P < 0.05 for
both). When the OD readings of the E1 levels in patients
Correlation between levels of core and E1 antigens: ELISA  was performed on circulating antigens in 65 HCV infected  patients using rabbit anti core or anti E1 as primary antibod- ies Figure 3
Correlation between levels of core and E1 antigens: ELISA 
was performed on circulating antigens in 65 HCV infected 
patients using rabbit anti core or anti E1 as primary antibod-
ies. The OD readings obtained for both antigens were corre-
lated. The results revealed strong positive correlation 
between levels of both antigens. Correlation coefficient (r = 
0.98) and P-value (<0.0001).
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Western blot analysis of serum samples from Hepatitis C virus  infected and noninfected individuals with antisera monospe- cific to the Core (Fig. 2a) and E1 (Fig.2b) region of HCV. Fig.  2a Figure 2
Western blot analysis of serum samples from Hepatitis C virus 
infected and noninfected individuals with antisera monospe-
cific to the Core (Fig. 2a) and E1 (Fig.2b) region of HCV. Fig. 
2a. A single band was identified at 38 kDa in serum samples 
from infected individuals only, lanes 1 to 3, serum samples 
from three individuals infected with Hepatitis C virus ; lanes 4 
to 6, serum samples from three noninfected healthy individu-
als. Fig. 2b. A single band was identified at 88 kDa in serum 
samples from infected individuals only, lanes 3 and 4, serum 
samples from two individuals infected with Hepatitis C virus ; 
lanes 1 and 2, serum samples from two noninfected healthy 
individuals. Molecular mass bands are not shown but are indi-
cated by arrows.
A
B
Table 1: Mean OD values of both core and envelope circulating HCV antigens in precipitated immune complexes from HCV infected 
individuals and uninfected healthy controls
Mean OD values
Core Envelope
Infected Control Infected Control
0.697 0.286 0.644 0.286
P < 0.0001 P < 0.0003
Cut off = 0.4Virology Journal 2006, 3:67 http://www.virologyj.com/content/3/1/67
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sera were compared with ALT and AST levels, results
showed positive correlation (r = 0.43, 0.64 for ALT and
AST respectively; P < 0.05 for both (Fig. 5C &5D).
7. Correlation between HCV load with levels of ALT and 
AST
Comparing the HCV load in infected patients with serum
ALT and AST levels revealed extremely poor correlation (r
= 0.022 and 0.002 respectively) (Fig 6a &6b).
Discussion
Monitoring the pathogenesis of human HCV disease has
been a conflicting issue. Several investigators have looked
for laboratory tools that can monitor progress in liver
pathogenesis and response to antiviral treatments, yet, the
obtained results did not allow clear conclusions and dra-
matically varied among different HCV genotypes [34,35].
These inter-individual variations in diagnosing active
infection, responsiveness to treatment and development
of symptoms could be due to the extensive mutational
rates in HCV genome followed by emergence of several
quasispecies in a single patient [[36-38] and [8]]. Thus the
present study was designed to demonstrate the complexity
in diagnosing HCV and to discuss whether testing the lev-
els of viral antigens correlates with the severity of the dis-
ease and whether the available tools including the
quantification of viral load are reliable. Measurements of
anti-HCV core and E1 antibodies were expected to be
more useful than viral load in better diagnosis of active
HCV infection since they will detect viral proteins which
reflect the ability of assembling viral particles and subse-
quent intracellular inflammatory reactions, not only the
Correlation between levels of both HCV core and E1 anti- gens with the serum levels of ALT and AST Figure 5
Correlation between levels of both HCV core and E1 anti-
gens with the serum levels of ALT and AST. Results showed 
generally positive correlation between the level of the core 
antigen and both enzymes and the correlation coefficient val-
ues were (A; r = 0.44, P value is 0.008) for ALT and (B; r = 
0.47, P value is 0.003) for AST. And also positive correlation 
between E1 and both enzymes. The correlation coefficient 
values were (C; r = 0.43, P is 0.0075) for ALT and (D; r = 
0.64, P is 0.0001) for AST.
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Correlation between levels of both HCV core (A) and 
envelop (B) antigens with viral copy number quantitation 
results obtained by branched DNA assay. The results 
reflected the presence of negative correlation for OD values 
of both antigens when compared to the branched DNA viral 
copy number values and the correlation coefficients were (r 
= -0.36 (A), -0.39 (B)) for both core-branched DNA and 
envelop-branched DNA. These values were not extremely 
significant in case of core-branched DNA (P < 0.06) but was 
clearly significant for envelop-branched DNA (P < 0.05).
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existence of viral RNA. The anti-synthetic peptide antibod-
ies used in the present study have recently been shown
sensitive to detect viral core and E1 antigens in PBMCs
derived from HCV infected patients [39]. Furthermore,
the conserved viral core and E1 peptides that were used to
develop the polyclonal antibodies in rabbits were recog-
nized by human anti- HCV IgG antibodies in more than
90 % of infected patients [30] thus suggesting that these
two peptides are immunogenic in humans and rabbits.
The results presented herein clearly demonstrate that our
polyclonal antibodies are 100% sensitive since they were
able to detect viral antigens in all HCV RNA positive cases.
Viral genotyping revealed that all cases included contain
HCV genotype 4, probably explaining disagreement with
previous reports on genotypes 1 and 2 that displayed pos-
itive correlation between core levels and viral loads
[[40,41] and [42]]. This disagreement could likely be due
to differences in the nature and antigenicity of the
detected core epitopes in our study than in previous
reports. Noteworthy, our anti E1 antibodies were raised
specifically against conserved peptides [30] among nearly
all the reported viral genotypes. The observed high degree
of correlation between core and E1 levels (r = 0.98) sup-
ports the earlier hypothesis that both proteins are cleaved
simultaneously during processing of viral polyprotein
precursor [43]. In addition, since bDNA is an assay testing
genomic copy number based on untranslated sequence of
the virus, thus from our particular point of view it has
nothing to do with expressed viral proteins (whether core
or E1), and hence, one can very much accept absence of
correlation between circulating viral antigens and viral
loads. Also, the over sensitivity of the bDNA can come at
the expense of its specificity and may question its value as
a proper and realistic tool for monitoring the existence of
the virus especially in following up the response to treat-
ment Our hypotheses are not only speculative but were
also based on our frequent observations among HCV gen-
otype 4 infected patients with high copy number who nei-
ther had pathogenic symptoms, abnormal ultrasound
findings nor abnormal profile of liver enzymes (our
unpublished data). Noteworthy, immune complexes pre-
cipitated from sera of those subjects also showed undetec-
table levels of HCV core and E1 antigens. Our data clearly
demonstrate the absence of correlation between viral copy
number as measured by bDNA with either levels of ALT or
AST and this was in agreement with McCormick et al.,
[18]; Yeo et al., [20]; Anand and Velez, [44] and contra-
dictory to results obtained by Beld et al., [45]; Sabin et al.,
[17] and Hassan et al., [16]. Although it seems conflicting
that results of Hassan et al., [16] and ours are contradict-
ing while the study populations in both reports were
Egyptians, this is not surprising particularly under the ran-
dom available treatments in Egypt (natural products, liver
supportive drugs, antiviral drugs and interferon) which
may lead to lowering liver enzymes while having no effect
on different viral quasispecies that may exist in infected
patients or may result in emergence of new quasispecies
with various degrees of aggression. To avoid such con-
flicts, one has to recruit properly characterized patients
who have been certainly receiving no treatment before
getting enrolled into such studies. A major scientific
advantage of this study is the development of a serological
system that can be automated for high throughput analy-
sis. Once this system is available, one can pick up early
infected subjects via massive screening programs in heav-
ily infected areas.
HCV antigens were detected in serum, blood mononu-
clear cells and liver tissues from infected patients [[46,40]
and [47]]. In the present study, sera of HCV infected
patients were used to provide direct proof on the specifi-
city of the antibodies used in the current study by showing
single and discrete bands in western blotting analysis. The
immunogenic protein bands around ~38 kDa for core and
~88 kDa for E1 were only found in sera of HCV patients
but not in sera from the healthy controls. Zhang et al.,
Correlation of HCV load with ALT and AST levels Figure 6
Correlation of HCV load with ALT and AST levels. Linear 
regression analysis of HCV load with either serum ALT or 
AST levels was performed in infected patients. Values of cor-
relation coeffecient showed extremely poor correlation 
between viral copy number and levels of either liver enzyme 
(A; r = 0.22 for ALT and B; r = 0.002 for AST)
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[48] found a fusion protein of 32 kDa of HCV core protein
exhibiting specific reaction with HCV-positive serum.
Also, Choukhi et al., [49] found a 90 kDa band of E1/E2
heterodimer in infected but not in healthy subjects. Fur-
ther investigations on the structure of the target HCV core
and E1 serum  antigens are required. In conclusion we
present a new combination of serological tools correlating
with liver enzyme levels that could be utilized as supple-
mental tests to viral load testing. This new combination of
tests would probably allow clinicians to get to better con-
clusions about not only the severity of liver pathogenesis
in viremic patients but also for following up longitudi-
nally the responsiveness of those patients to whichever
antiviral therapy by tracing the titers of core or E1 together
with viral loads and liver enzyme levels. Such combina-
tion of tools should provide significant data on the selec-
tion criteria for the initiation of antiviral therapy and also
for deciding whether to continue or terminate the selected
antiviral treatment. Furthermore, the development of
direct immunoassay test for viral activity should allow
cheap and efficient screening for acute and early infec-
tions in areas where the viral burden is high.
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